<prompt> Please answer with one of the option in the bracket. Write reasoning in between . Write answer in between .Q:A 24-year-old woman comes to the physician because of a 3-day history of lower abdominal pain and dysuria. She has a history of recurring urinary tract infections that have resolved with antibiotic treatment. She is sexually active with one male partner and they do not use condoms. She had mild pain during her last sexual intercourse one week ago. Her temperature is 38.2C 100.8F, pulse is 86min, and blood pressure is 11070 mm Hg. Physical examination shows lower abdominal tenderness and bilateral inguinal lymphadenopathy. There is a small amount of purulent vaginal discharge. Bimanual examination shows uterine and cervical motion tenderness. Laboratory studies show:Hemoglobin 12 gdLLeukocyte count 13,500mm3Segmented neutrophils 75Eosinophils 1Lymphocytes 22Monocytes 2Platelet count 328,000mm3Erythrocyte sedimentation rate 82 mmhUrineRBC 12hpfWBC 01hpfNitrite negativeBacteria occasionalUrine pregnancy test negativeWhich of the following is the most appropriate pharmacotherapy?? A: Oral metronidazole, B: Intramuscular leuprolide, C: Oral levofloxacin and azithromycin, D: Oral trimethoprim-sulfamethoxazole, E: Intramuscular ceftriaxone and oral doxycycline,  <response>: This is a clinical case of a 24-year-old woman with symptoms and findings consistent with pelvic inflammatory disease PID. The key findings are lower abdominal pain, dysuria, purulent vaginal discharge, cervical motion tenderness on exam, and lab results showing leukocytosis with a left shift and elevated ESR. The diagnosis is likely PID caused by a sexually transmitted infection such as chlamydia or gonorrhea. The treatment should cover likely organisms including Neisseria gonorrhoeae, Chlamydia trachomatis, and anaerobes.Choice A, metronidazole, only covers anaerobes. Choice B, leuprolide, is used for endometriosis and would not treat an acute PID infection. Choice D, TMP-SMX, does not have ideal coverage for gonorrhea. Choice C, levofloxacin and azithromycin, provides reasonable coverage but has emerging resistance issues. Choice E, ceftriaxone and doxycycline, provides the broadest coverage for likely organisms causing PID.E: Intramuscular ceftriaxone and oral doxycycline 